Analysts’ recommendations for ABT
Abbott Laboratories (ABT) reported its 1Q18 results on April 18. Let’s look at Wall Street analysts’ recommendations for ABT stock after its earnings release. On May 2, a Reuters survey noted that 20 brokerage firms were tracking ABT. Of these firms, 16 analysts recommended a “buy” or “strong buy.” The rest of the firms gave a “hold” rating on the stock. None of the firms gave a “sell” recommendation for Abbott Laboratories.
The chart below shows a 12-month recommendation summary for ABT stock over the last few months.
On May 2, Abbott Laboratories (ABT) had a consensus 12-month target price of $68.56, implying a 12-month investment return potential of ~17.7%. This return is based on the stock’s closing price of $59.19 on April 20.
ABT’s peers Edwards Lifesciences (EW), Medtronic (MDT), and Boston Scientific (BSX) had average analyst target prices of $145.95, $91.37, and $32.72, respectively. These price targets imply 12-month returns of 10.4%, 13.6%, and 11%, respectively.
Revisions and updates
On April 19, following Abbott Laboratories’ 1Q18 earnings results, Jefferies decreased its price target on ABT stock from $69.00 to $68.00. On April 18, however, BMO Capital placed Abbott Laboratories among its top picks for fiscal 2018. BMO Capital has a “buy” rating on ABT stock. RBC Capital Markets maintained its “outperform” rating on ABT stock after its 1Q18 earnings release.
Be sure to check out all the data we’ve added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data, as well as dividend information. Take a look!